Bladder cancer: open trials in Portugal

3 open trials have a site in Portugal. Registry data; only the trial team decides who can take part.

NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Trial Treatment · Phase 1/2 · Daiichi Sankyo
Champalimaud Clinical Centre, Lisbon · Unidade Local De Saude De Santa Maria E.P.E., Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local De Saude De Santo Antonio E.P.E., Porto
Registry updated 2026-10-26
2024-518348-19-00
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Trial Treatment · Phase 1 · Novartis Pharma AG
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-21
NCT07784387
A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
Research · Janssen-Cilag Farmaceutica Ltda.
IPO Lisboa, Lisbon
Registry updated 2026-08-28

This page is not medical advice. Talk to your doctor before contacting a trial.

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)